#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14788	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2098	698.3	0	.	n	.	0	C451T	SNP	451	451	C	633	633	T	851	T,C	586,204	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14788	16S	1529	1529	99.93	16S.l15.c30.ctg.1	2098	698.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1366	1366	C	877	C	813	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27662	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3667	752.4	0	.	n	.	0	T695C	SNP	695	695	T	1113	1113	C	846	C	788	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27662	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3667	752.4	0	.	n	.	0	A1638G	SNP	1638	1638	A	2056	2056	G	892	G,A	394,442	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27662	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3667	752.4	0	.	n	.	0	T1971C	SNP	1971	1971	T	2389	2389	C	832	C,A,T	769,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27662	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3667	752.4	1	SNP	n	A2045G	0	.	.	2045	2045	A	2463	2463	A	840	A	788	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27662	23S	2890	2890	99.9	23S.l6.c30.ctg.1	3667	752.4	1	SNP	n	C2597T	0	.	.	2597	2597	C	3015	3015	C	877	C	812	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_Y_01480c	folP.WHO_Y_01480c	1	1	27	1844	folP	855	855	100.0	folP.l15.c4.ctg.1	1523	120.3	1	SNP	p	R229S	1	.	.	685	687	AGC	1007	1009	AGC	168;166;168	A;G;C	153;151;148	folP.WHO_Y_01480c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5064	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3499	144.4	1	SNP	p	S91F	1	.	.	271	273	TTC	611	613	TTC	175;177;179	T;T;C,T	161;164;163,1	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5064	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3499	144.4	1	SNP	p	G95N	0	.	.	283	285	GGC	623	625	GGC	177;174;170	G;G;C	160;156;153	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	5064	gyrA	2751	2751	99.85	gyrA.l15.c30.ctg.1	3499	144.4	1	SNP	p	D95G	1	.	.	283	285	GGC	623	625	GGC	177;174;170	G;G;C	160;156;153	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1640	mtrR	633	633	100.0	mtrR.l6.c30.ctg.1	1276	127.9	1	SNP	p	G45D	0	.	.	133	135	GGC	410	412	GGC	206;205;207	G;G;C	199;198;201	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	782	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	983	79.3	0	.	n	.	0	A197.	DEL	197	197	A	558	558	A	208	A	188	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5520	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	188.8	1	SNP	p	D86N	0	.	.	256	258	GAC	590	592	GAC	248;249;248	G,T;A;C	227,1;230;230	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5520	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	188.8	1	SNP	p	R87W	0	.	.	259	261	CGT	593	595	CGT	247;245;247	C;G;T	231;227;227	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5520	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	188.8	1	SNP	p	S87R	1	.	.	259	261	CGT	593	595	CGT	247;245;247	C;G;T	231;227;227	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5520	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	188.8	1	SNP	p	R87I	0	.	.	259	261	CGT	593	595	CGT	247;245;247	C;G;T	231;227;227	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5520	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2915	188.8	1	SNP	p	S88P	0	.	.	262	264	TCC	596	598	TCC	248;251;253	T;C;C	229;232;234	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4028	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2615	153.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1554	1556	GGC	185;187;184	G;G;C	172;174;171	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	A311V	0	.	.	931	933	GCC	1305	1307	GCC	204;204;205	G;C,A;C	185;185,1;188	penA.35.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	I312M	1	.	.	934	936	ATG	1308	1310	ATG	206;206;211	A;T;G	190;188;192	penA.35.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	V316T	1	.	.	946	948	ACC	1320	1322	ACC	209;212;211	A;C;C	188;196;194	penA.35.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	T316P	0	.	.	946	948	ACC	1320	1322	ACC	209;212;211	A;C;C	188;196;194	penA.35.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1821	1823	ACC	182;181;183	A;C,A;C	162;165,1;166	penA.35.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1875	1877	GCG	186;187;190	G;C,T,G;G	166;150,1,1;156	penA.35.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1875	1877	GCG	186;187;190	G;C,T,G;G	166;150,1,1;156	penA.35.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1998	2000	GGT	169;166;165	G;G;T	153;151;149	penA.35.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	G545S	0	.	.	1633	1635	GGC	2007	2009	GGC	161;158;156	G;G;C,T	150;145;144,1	penA.35.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.35.001	penA.35.001	1	1	27	3824	penA	1746	1746	100.0	penA.l15.c17.ctg.1	2376	160.0	1	SNP	p	P551S	0	.	.	1651	1653	CCG	2025	2027	CCG	142;141;136	C,CG;C;G	101,1;108;100	penA.35.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5844	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3174	183.6	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1618	1620	CCG	231;231;232	C;C;G	205;212;206	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2512	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1749	142.5	0	.	p	.	0	M83fs	FSHIFT	247	247	A	479	479	C	168	C	157	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	270	porB1a	984	272	90.58	porB1a.l6.c17.ctg.2	323	26.8	0	.	p	.	0	H217N	NONSYN	649	651	CAT	76	78	AAT	14;14;14	A;A;T	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	270	porB1a	984	272	90.58	porB1a.l6.c17.ctg.2	323	26.8	0	.	p	.	0	D218N	NONSYN	652	654	GAT	79	81	AAT	15;15;15	A;A;T	14;14;14	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	270	porB1a	984	272	90.58	porB1a.l6.c17.ctg.2	323	26.8	0	.	p	.	0	V226A	NONSYN	676	678	GTA	103	105	GCA	16;16;16	G;C;A	16;16;16	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	270	porB1a	984	272	90.58	porB1a.l6.c17.ctg.2	323	26.8	0	.	p	.	0	.	MULTIPLE	700	702	ACT	126	128	GTA	13;13;13	G;T;A	13;13;13	.	.
porB1a.WHO_G_02195c	porB1a.WHO_G_02195c	1	0	528	270	porB1a	984	272	90.58	porB1a.l6.c17.ctg.2	323	26.8	0	.	p	.	0	N237fs	FSHIFT	709	709	A	135	135	A	12	A	12	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2858	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1577	179.9	0	.	p	.	0	I45V	NONSYN	133	135	ATT	407	409	GTT	244;242;239	G;T;T	226;223;220	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2858	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1577	179.9	1	SNP	p	G120K	1	.	.	358	360	AAG	632	634	AAG	243;245;245	A;A;G	223;227;224	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2858	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1577	179.9	1	SNP	p	N121D	0	.	.	361	363	AAC	635	637	AAC	250;248;248	A;A;C	230;230;229	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	539	2858	porB1b	1038	1038	99.9	porB1b.l6.c4.ctg.1	1577	179.9	1	SNP	p	A121N	1	.	.	361	363	AAC	635	637	AAC	250;248;248	A;A;C	230;230;229	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	10656	rpoB	4179	4179	99.98	rpoB.l6.c4.ctg.1	4766	223.0	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1092	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1085	99.8	1	SNP	p	V57M	1	.	.	169	171	ATG	572	574	ATG	230;231;235	A;T;G	212;216;218	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
